keyword
MENU ▼
Read by QxMD icon Read
search

Prolia

keyword
https://www.readbyqxmd.com/read/27576482/utilization-and-cost-of-anti-osteoporosis-therapy-among-us-medicare-beneficiaries
#1
Smita Jha, Timothy Bhattacharyya
UNLABELLED: There is a strong impetus to prevent and treat osteoporosis to prevent fractures. $990 million dollars was spent on anti-osteoporosis drugs in 2013. As we shift our focus on primary prevention of fractures, providers are encouraged to find the most cost-effective anti-osteoporosis therapy for patients. PURPOSE: Osteoporosis is a major global problem with osteoporotic fractures posing a potentially avoidable burden on healthcare resources. We studied the utilization and cost of anti-osteoporotic therapy using the 2013 Medicare Part D data...
December 2016: Archives of Osteoporosis
https://www.readbyqxmd.com/read/27338901/denosumab-a-case-of-mronj-with-resolution
#2
C V Lyttle, H Paterson
A patient was referred by a clinical oncologist regarding a non-healing area of bone in the lower jaw. The patient was taking denosumab (Prolia(®), Xgeva(®)) when they had a tooth extracted and the area failed to heal. Following suspension of the drug, the area healed with mucosal coverage. This new class of drugs are being increasingly used as an alternative antiresorptive drug to bisphosphonates and are licenced in the UK for prevention of osteoporotic fractures and prevention of skeletal-related events (SREs) in patients with metastatic cancer...
June 24, 2016: British Dental Journal
https://www.readbyqxmd.com/read/27042724/denosumab-prolia-and-male-osteoporosis-do-not-use-in-men-or-in-women
#3
(no author information available yet)
No proven efficacy in preventing osteoporotic fractures in men, but serious adverse effects including atypical fractures and symptomatic hypocalcaemia.
February 2016: Prescrire International
https://www.readbyqxmd.com/read/26964445/denosumab-an-alternative-to-bisphosphonates-but-also-associated-with-osteonecrosis-of-the-jaw-what-is-the-risk
#4
Harlene Kaur Sidhu
Most dental professionals will have, or will soon, encounter patients prescribed this novel alternative antiresorptive drug to bisphosphonates, denosumab (Prolia®, Xgeva®). Denosumab is licensed in the UK for the prevention of osteoporotic fractures in postmenopausal women and the prevention of skeletal-related events (SRE) in adults with bone metastases. The presence of osteonecrosis of the jaw in patients receiving non-bisphosphonate antiresorptives has led to the introduction of the term antiresorptive-related osteonecrosis of the jaw or ARONJ...
June 2015: Dental Update
https://www.readbyqxmd.com/read/26881176/the-effects-of-noncompliance-to-prolia-denosumab-on-the-changes-in-bone-mineral-density-a-retrospective-review
#5
Matthew Wong-Pack, Aashish Kalani, Jacob Hordyk, George Ioannidis, Robert Bensen, William G Bensen, Alexandra Papaioannou, Jonathan D Adachi, Arthur N Lau
Although denosumab (Prolia) has been shown to be a safe and efficacious therapy for osteoporotic patients in numerous clinical trials, few studies have determined its effectiveness in real world clinical practice. A retrospective review of patients prescribed Prolia assessing the impact that noncompliance from the regular dosing regimen of six months for denosumab has on bone mineral density (BMD) was performed. 924 patient records were reviewed between August 2012 and September 2013 with 436 patients meeting the eligibility criteria...
2016: Journal of Osteoporosis
https://www.readbyqxmd.com/read/25783691/-therapy-of-bone-marrow-edema-syndrome-in-the-knee-with-denosumab-case-report
#6
T Geith, W Mutschler, F Berger
BACKGROUND: The bone marrow edema syndrome (BMES) is a painful joint disease which usually affects healthy middle aged persons. It is usually treated conservatively. AIM: This case report describes the clinical history of a patient with BMES and a therapy attempt with denosumab. RESULTS AND DISCUSSION: Complete restitution of the bone marrow edema in the knee and the disappearance of clinical complaints were observed 8 weeks after a single therapy with 60 mg denosumab (Prolia®) as a subcutaneous injection...
March 2015: Der Unfallchirurg
https://www.readbyqxmd.com/read/25509894/-preliminary-results-of-an-open-label-observational-study-evaluating-the-efficacy-and-safety-of-prolia-used-in-women-with-postmenopausal-osteoporosis
#7
O B Ershova, O M Lesniak, K Iu Belova, A V Nazarova, A V Manovitskaia, T M Musaeva, R M Musraev, R Z Nurlygaianov, L Ia Rozhinskaia, I A Skripnikova, N V Toroptsova
AIM: To evaluate the efficacy and safety of Denosumab (Prolia), a first-line osteoporosis (OP) medication that is a fully human monoclonal antibody to the receptor activator of nuclear factor xB ligand (RANKL), within an open-label observational study. SUBJECTS AND METHODS: Patients aged 50 years or older with postmenopausal OP, who were treated with Prolia in clinical practice, were examined. The concentrations of the bone resorption (BR) marker of C-terminal telopeptide and other laboratory indicators (total serum calcium, total alkaline phosphatase, and creatinine) were measured following 3 months...
2014: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/25370317/comparison-of-the-efficacy-adverse-effects-and-cost-of-zoledronic-acid-and-denosumab-in-the-treatment-of-osteoporosis
#8
COMPARATIVE STUDY
Kellen C Sheedy, Maria I Camara, Pauline M Camacho
OBJECTIVE: Injectable osteoporosis drugs are increasing in popularity due to their efficacy and convenient administration. In this retrospective comparison of the two available treatments, denosumab (Prolia®) and zoledronic acid (ZA, Reclast®), we aimed to determine and compare the efficacy and tolerability of denosumab and ZA. METHODS: The charts of patients who received denosumab and ZA at Loyola Hospital were reviewed, and adverse events were noted. Of primary interest were myalgias, flu-like symptoms, back pain, and fractures...
March 2015: Endocrine Practice
https://www.readbyqxmd.com/read/25052047/development-and-evaluation-of-an-algorithm-to-identify-users-of-prolia-%C3%A2-during-the-early-postmarketing-period-using-health-insurance-claims-data
#9
Veena Hoffman, Fei Xue, Betsey Gardstein, Kathleen Skerry, Cathy W Critchlow, Cheryl Enger
PURPOSE: The goal of this study is to develop and validate an algorithm to identify Prolia(®) users within a health insurance claims database. METHODS: Patients with a denosumab-specific or nonspecific administration claim during the early period of Prolia availability in the USA (June 1, 2010 to March 31, 2012) were classified as definite, probable, possible, and nonusers of Prolia using an algorithm consisting of nine different components based on claims patterns consistent with Prolia use...
September 2014: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/24935243/denosumab-a-review-of-its-use-in-postmenopausal-women-with-osteoporosis
#10
REVIEW
Lesley J Scott
Subcutaneous denosumab (Prolia(®) [USA, Europe]; Pralia(®) [Japan]) once every 6 months is indicated in several countries for the treatment of postmenopausal women with osteoporosis at increased or high risk for fractures (featured indication). In some countries, it is also indicated for use in postmenopausal women who have failed or are intolerant to other osteoporosis treatments. In several international, phase III trials (≤3 years' duration) involving more than 12,000 women with postmenopausal osteoporosis or low bone mineral density (BMD), including Asian studies, denosumab was an effective and generally well tolerated treatment...
July 2014: Drugs & Aging
https://www.readbyqxmd.com/read/24534414/systematic-review-of-the-use-of-bone-turnover-markers-for-monitoring-the-response-to-osteoporosis-treatment-the-secondary-prevention-of-fractures-and-primary-prevention-of-fractures-in-high-risk-groups
#11
REVIEW
Jane Burch, Stephen Rice, Huiqin Yang, Aileen Neilson, Lisa Stirk, Roger Francis, Paul Holloway, Peter Selby, Dawn Craig
BACKGROUND: There is currently no standard practice for the monitoring of patients receiving treatment for osteoporosis. Repeated dual-energy X-ray absorptiometry (DXA) is commonly used for monitoring treatment response, but it has its limitations. Bone turnover markers have advantages over DXA as they are non-invasive, relatively cheap and can detect changes in bone turnover rates earlier. However, they do have disadvantages, particularly high within- and between-patient variability...
February 2014: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/23857864/design-and-methods-of-a-postmarketing-pharmacoepidemiology-study-assessing-long-term-safety-of-prolia%C3%A2-denosumab-for-the-treatment-of-postmenopausal-osteoporosis
#12
Fei Xue, Haijun Ma, Catherine Stehman-Breen, Christine Haller, Leonid Katz, Rachel B Wagman, Cathy W Critchlow
PURPOSE: To describe the rationale and methods for a prospective, open-cohort study assessing the long-term safety of Prolia(®) for treatment of postmenopausal osteoporosis (PMO) in postmarketing settings. METHODS: Data will be derived from United States Medicare, United Healthcare, and Nordic (Denmark, Sweden, Norway) national registries. Observation will begin on the date of first Prolia(®) regulatory approval (May 26, 2010) and continue for 10 years. Women with PMO will be identified by postmenopausal age, osteoporosis diagnosis, osteoporotic fracture, or osteoporosis treatment...
October 2013: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/23569491/treatment-of-facioscapulohumeral-muscular-dystrophy-with-denosumab
#13
Stanley S Lefkowitz, Doris L Lefkowitz, Jeremy Kethley
BACKGROUND: Facioscapulohumeral muscular dystrophy (FSHD) is the 3(rd) most common form of muscular dystrophy. Effective treatments for any of the muscular dystrophies have yet to be realized. This report describes such a treatment. CASE REPORT: A 66 year old female was diagnosed with osteoporosis. She had been diagnosed with FSHD muscular dystrophy a number of years previously by both genetic and clinical studies. Following a 2 year course with Forteo for osteoporosis, she was given an injection of Denosumab (Prolia) to maintain her bone density...
2012: American Journal of Case Reports
https://www.readbyqxmd.com/read/23334374/improved-real-life-adherence-of-6-monthly-denosumab-injections-due-to-positive-feedback-based-on-rapid-6-month-bmd-increase-and-good-safety-profile
#14
J D Ringe, P Farahmand
Almost 50 % of osteoporosis (OP) patients discontinue bisphosphonate (BP) therapy within 1-2 years after the start of their treatment. Denosumab's longer dosing interval with its administration every 6 months (Q6M) as a subcutaneous (sc) injection might result in a better real-life treatment adherence and persistence than weekly or monthly oral BP treatment regimen. The objectives of this open, investigator-initiated, prospective, observational, single-center study were to evaluate adherence with denosumab 60 mg sc every 6 months (Q6M) (Prolia(®)) injections in osteoporotic patients in a routine clinical care setting and to describe whether positive feedback to OP patients based on measured bone mineral density (BMD) increases and good safety profile have an impact on patients' real-life adherence...
May 2014: Rheumatology International
https://www.readbyqxmd.com/read/22335312/denosumab-prolia-for-treatment-of-postmenopausal-osteoporosis
#15
REVIEW
Gretchen L Johnson
No abstract text is available yet for this article.
February 15, 2012: American Family Physician
https://www.readbyqxmd.com/read/22276325/ask-the-doctor-i-m-looking-for-information-on-prolia-and-reclast-as-alternatives-to-boniva
#16
Celeste Robb-Nicholson
No abstract text is available yet for this article.
November 2011: Harvard Women's Health Watch
https://www.readbyqxmd.com/read/22241889/denosumab-for-postmenopausal-osteoporosis
#17
REVIEW
(no author information available yet)
Osteoporosis is the most common clinical disorder of bone metabolism, and is characterised by low bone mass and deterioration of the microarchitecture of bone tissue that results in increased bone fragility and susceptibility to bone fracture. In the UK, it is estimated that osteoporosis affects over 3 million people and leads to 230,000 fractures per year. It occurs most commonly in postmenopausal women and prevalence increases markedly with age, from 2% in women at 50 years to more than 25% at 80 years of age...
January 2012: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/22087866/population-pharmacokinetic-meta-analysis-of-denosumab-in-healthy-subjects-and-postmenopausal-women-with-osteopenia-or-osteoporosis
#18
Liviawati Sutjandra, Rachelle D Rodriguez, Sameer Doshi, Mark Ma, Mark C Peterson, Graham R Jang, Andrew T Chow, Juan José Pérez-Ruixo
BACKGROUND AND OBJECTIVE: Inhibition of the receptor activator of nuclear factor κ-B ligand (RANKL) is a therapeutic target for treatment of bone disorders associated with increased bone resorption, such as osteoporosis. The objective of this analysis was to characterize the population pharmacokinetics of denosumab (AMG 162; Prolia®), a fully human IgG2 monoclonal antibody that binds to RANKL, in healthy subjects and postmenopausal women with osteopenia or osteoporosis. METHODS: A total of 22944 serum free denosumab concentrations from 495 healthy subjects and 1069 postmenopausal women with osteopenia or osteoporosis were pooled...
December 1, 2011: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/22023901/the-rankl-pathway-and-denosumab
#19
REVIEW
Robin K Dore
Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor-κB ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts. It was approved by the Food and Drug Administration in June 2010 as a new treatment for postmenopausal osteoporosis in women who are at high risk for fracture. Given its mechanism of action, it is an antiresorptive therapy that is administered as a 60-mg subcutaneous injection every 6 months. It is the first biologic antiresorptive therapy for osteoporosis, and the first osteoporosis therapy to show efficacy and safety in patients with renal impairment...
August 2011: Rheumatic Diseases Clinics of North America
https://www.readbyqxmd.com/read/21815702/spotlight-on-denosumab-in-postmenopausal-osteoporosis
#20
Marit D Moen, Susan J Keam
Denosumab (Prolia®) is a human recombinant monoclonal antibody that is approved for the treatment of postmenopausal osteoporosis in women at high or increased risk of fracture in the US, the EU, and several other countries. Denosumab has a novel mechanism of action; it binds to receptor activator of nuclear factor κB ligand and inhibits bone resorption by inhibiting osteoclast formation, function, and survival. In postmenopausal women with osteoporosis, denosumab reduced the risk of vertebral, nonvertebral, and hip fractures compared with placebo over 3 years in the large, phase III FREEDOM study...
August 1, 2011: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
keyword
keyword
9139
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"